A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer
Status:
Terminated
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, open label Phase 1b/2 study in patients with metastatic colorectal
carcinoma. The Phase 1b will identify the dose of the combination of PF-05212384 plus
FOLFIRI. The randomized, two-arm Phase 2 portion will compare the efficacy and safety of
PF-05212384 plus FOLFIRI to that of bevacizumab plus FOLFIRI.
The study population will consist of patients with mCRC previously treated with an
oxaliplatin-based regimen in the first line setting or who have progressed within 6 months of
the end of an adjuvant oxaliplatin-based regimen.